CKD Bio Corp. (063160.KS)
KRW 22500.0
(-1.96%)
KRW 22500.0
(-1.96%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 146.92 Billion KRW | 5.76% |
| 2022 | 138.92 Billion KRW | 27.01% |
| 2021 | 109.37 Billion KRW | 36.99% |
| 2020 | 79.84 Billion KRW | 181.38% |
| 2019 | 28.37 Billion KRW | 477.57% |
| 2018 | 4.91 Billion KRW | -18.39% |
| 2017 | 6.01 Billion KRW | -45.45% |
| 2016 | 11.03 Billion KRW | 28.88% |
| 2015 | 8.56 Billion KRW | -16.56% |
| 2014 | 10.26 Billion KRW | -40.26% |
| 2013 | 17.17 Billion KRW | -40.08% |
| 2012 | 28.66 Billion KRW | -11.86% |
| 2011 | 32.52 Billion KRW | 148.78% |
| 2010 | 13.07 Billion KRW | -28.85% |
| 2009 | 18.37 Billion KRW | -21.99% |
| 2008 | 23.55 Billion KRW | -11.32% |
| 2007 | 26.56 Billion KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 141.94 Billion KRW | -4.08% |
| 2024 Q1 | 147.98 Billion KRW | 0.72% |
| 2023 Q2 | 142.01 Billion KRW | -0.12% |
| 2023 Q3 | 159.12 Billion KRW | 12.05% |
| 2023 Q4 | 146.92 Billion KRW | -7.67% |
| 2023 FY | 146.92 Billion KRW | 5.76% |
| 2023 Q1 | 142.19 Billion KRW | 2.35% |
| 2022 Q3 | 121.36 Billion KRW | 8.82% |
| 2022 Q2 | 111.52 Billion KRW | 2.48% |
| 2022 FY | 138.92 Billion KRW | 27.01% |
| 2022 Q1 | 108.83 Billion KRW | -0.5% |
| 2022 Q4 | 138.92 Billion KRW | 14.47% |
| 2021 FY | 109.37 Billion KRW | 36.99% |
| 2021 Q2 | 96.85 Billion KRW | 3.19% |
| 2021 Q1 | 93.85 Billion KRW | 17.55% |
| 2021 Q4 | 109.37 Billion KRW | 4.11% |
| 2021 Q3 | 105.06 Billion KRW | 8.48% |
| 2020 Q4 | 79.84 Billion KRW | -0.54% |
| 2020 Q1 | 43.1 Billion KRW | 51.91% |
| 2020 Q2 | 61.39 Billion KRW | 42.42% |
| 2020 Q3 | 80.27 Billion KRW | 30.76% |
| 2020 FY | 79.84 Billion KRW | 181.38% |
| 2019 Q4 | 28.37 Billion KRW | 69.81% |
| 2019 FY | 28.37 Billion KRW | 477.57% |
| 2019 Q1 | 14.17 Billion KRW | 188.49% |
| 2019 Q2 | 11.81 Billion KRW | -16.64% |
| 2019 Q3 | 16.71 Billion KRW | 41.43% |
| 2018 FY | 4.91 Billion KRW | -18.39% |
| 2018 Q4 | 4.91 Billion KRW | -9.0% |
| 2018 Q3 | 5.39 Billion KRW | -5.88% |
| 2018 Q2 | 5.73 Billion KRW | -19.43% |
| 2018 Q1 | 7.11 Billion KRW | 18.26% |
| 2017 Q4 | 6.01 Billion KRW | -24.37% |
| 2017 FY | 6.01 Billion KRW | -45.45% |
| 2017 Q3 | 7.96 Billion KRW | -37.98% |
| 2017 Q2 | 12.83 Billion KRW | -4.36% |
| 2017 Q1 | 13.41 Billion KRW | 21.62% |
| 2016 Q2 | 5.8 Billion KRW | -63.83% |
| 2016 Q3 | 7.91 Billion KRW | 36.32% |
| 2016 FY | 11.03 Billion KRW | 28.88% |
| 2016 Q4 | 11.03 Billion KRW | 39.5% |
| 2016 Q1 | 16.04 Billion KRW | 87.35% |
| 2015 Q1 | 9.41 Billion KRW | -8.29% |
| 2015 Q3 | 12.84 Billion KRW | -11.79% |
| 2015 Q2 | 14.55 Billion KRW | 54.69% |
| 2015 Q4 | 8.56 Billion KRW | -33.32% |
| 2015 FY | 8.56 Billion KRW | -16.56% |
| 2014 FY | 10.26 Billion KRW | -40.26% |
| 2014 Q4 | 10.26 Billion KRW | -9.51% |
| 2014 Q3 | 11.34 Billion KRW | -23.98% |
| 2014 Q1 | 20.57 Billion KRW | 19.76% |
| 2014 Q2 | 14.91 Billion KRW | -27.48% |
| 2013 Q4 | 17.17 Billion KRW | -10.72% |
| 2013 FY | 17.17 Billion KRW | -40.08% |
| 2013 Q1 | 23.81 Billion KRW | -16.92% |
| 2013 Q2 | 19.79 Billion KRW | -16.88% |
| 2013 Q3 | 19.23 Billion KRW | -2.81% |
| 2012 Q2 | 25.52 Billion KRW | -8.38% |
| 2012 Q1 | 27.85 Billion KRW | -14.35% |
| 2012 Q3 | 28.1 Billion KRW | 10.15% |
| 2012 FY | 28.66 Billion KRW | -11.86% |
| 2012 Q4 | 28.66 Billion KRW | 1.97% |
| 2011 FY | 32.52 Billion KRW | 148.78% |
| 2011 Q4 | 32.52 Billion KRW | 3.53% |
| 2011 Q3 | 31.41 Billion KRW | 40.31% |
| 2011 Q2 | 22.38 Billion KRW | -9.68% |
| 2011 Q1 | 24.78 Billion KRW | 89.62% |
| 2010 Q1 | 16.37 Billion KRW | -10.88% |
| 2010 Q3 | 13.69 Billion KRW | -16.34% |
| 2010 Q4 | 13.07 Billion KRW | -4.57% |
| 2010 FY | 13.07 Billion KRW | -28.85% |
| 2010 Q2 | 16.37 Billion KRW | 0.0% |
| 2009 Q4 | 18.37 Billion KRW | 1.16% |
| 2009 FY | 18.37 Billion KRW | -21.99% |
| 2009 Q3 | 18.16 Billion KRW | -23.96% |
| 2009 Q2 | 23.88 Billion KRW | -1.06% |
| 2009 Q1 | 24.14 Billion KRW | 2.5% |
| 2008 Q1 | 26.74 Billion KRW | 0.7% |
| 2008 Q2 | 26.7 Billion KRW | -0.15% |
| 2008 Q3 | 23.68 Billion KRW | -11.31% |
| 2008 Q4 | 23.55 Billion KRW | -0.56% |
| 2008 FY | 23.55 Billion KRW | -11.32% |
| 2007 Q2 | 26.63 Billion KRW | 1.21% |
| 2007 FY | 26.56 Billion KRW | 0.0% |
| 2007 Q1 | 26.31 Billion KRW | 0.0% |
| 2007 Q4 | 26.56 Billion KRW | -0.16% |
| 2007 Q3 | 26.6 Billion KRW | -0.12% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -272.843% |
| Dong-A Socio Holdings Co., Ltd. | 691.88 Billion KRW | 78.764% |
| Ildong Holdings Co., Ltd. | 382.06 Billion KRW | 61.544% |
| HANDOK Inc. | 300.01 Billion KRW | 51.026% |
| Kukje Pharma Co., Ltd. | 30.66 Billion KRW | -379.18% |
| Yuhan Corporation | 230.07 Billion KRW | 36.139% |
| Dong-A ST Co., Ltd. | 406.7 Billion KRW | 63.874% |
| SAMSUNG PHARM. Co., LTD. | 595.48 Million KRW | -24573.424% |
| Hanmi Pharm. Co., Ltd. | 572.86 Billion KRW | 74.352% |
| Hanall Biopharma Co.,Ltd | 1.29 Billion KRW | -11284.994% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | -72.531% |
| Dong Sung Bio Pharm.Co.,Ltd. | 43.27 Billion KRW | -239.536% |
| MYUNGMOON Pharm co.,Ltd | 90.48 Billion KRW | -62.382% |
| Hana Pharm Co., Ltd. | 26.53 Billion KRW | -453.75% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -272.843% |
| Ilsung Pharmaceuticals Co., Ltd. | 238.12 Million KRW | -61601.252% |
| REYON Pharmaceutical Co., Ltd. | 225.05 Billion KRW | 34.715% |
| Aprogen pharmaceuticals,Inc. | 180.99 Billion KRW | 18.824% |
| JW Holdings Corporation | 554.58 Billion KRW | 73.507% |
| Ildong Pharmaceutical Co., Ltd. | 217.84 Billion KRW | 32.553% |
| Chong Kun Dang Pharmaceutical Corp. | 219.76 Billion KRW | 33.143% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 13.715% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | -218.358% |
| Hyundai Pharmaceutical Co., Ltd. | 39.2 Billion KRW | -274.766% |
| Samil Pharmaceutical Co.,Ltd | 175.87 Billion KRW | 16.462% |
| Jeil Pharmaceutical Co.,Ltd | 84.96 Billion KRW | -72.925% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -272.843% |
| Kwang Dong Pharmaceutical Co., Ltd. | 235.64 Billion KRW | 37.648% |
| Daewoong pharmaceutical Co.,Ltd | 469.68 Billion KRW | 68.718% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 13.715% |
| Yuhan Corporation | 230.07 Billion KRW | 36.139% |
| Jeil Pharma Holdings Inc | 173.03 Billion KRW | 15.086% |
| Yungjin Pharm. Co., Ltd. | 66.88 Billion KRW | -119.68% |
| Suheung Co., Ltd. | 467.85 Billion KRW | 68.596% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 13.715% |
| Samjin Pharmaceuticals Co., Ltd. | 118.63 Billion KRW | -23.844% |
| Korea United Pharm Inc. | 40.33 Billion KRW | -264.23% |
| Daewon Pharmaceutical Co., Ltd. | 146.04 Billion KRW | -0.6% |
| Dongwha Pharm.Co.,Ltd | 48.25 Billion KRW | -204.478% |
| Whan In Pharm Co.,Ltd. | 632.02 Million KRW | -23146.96% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | -218.358% |
| Chong Kun Dang Holdings Corp. | 468.03 Billion KRW | 68.608% |
| Boryung Corporation | 204.21 Billion KRW | 28.053% |
| Bukwang Pharmaceutical Co., Ltd. | 79.38 Billion KRW | -85.077% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | -72.531% |
| JW Lifescience Corporation | 46.31 Billion KRW | -217.248% |